Free Trial
OTCMKTS:ZLDPF

Zealand Pharma A/S 11/9/2023 Earnings Report

Zealand Pharma A/S logo
$75.15 +4.82 (+6.85%)
As of 05/2/2025 09:30 AM Eastern

Zealand Pharma A/S EPS Results

Actual EPS
$0.18
Consensus EPS
-$0.53
Beat/Miss
Beat by +$0.71
One Year Ago EPS
N/A

Zealand Pharma A/S Revenue Results

Actual Revenue
$43.16 million
Expected Revenue
$1.76 million
Beat/Miss
Beat by +$41.40 million
YoY Revenue Growth
N/A

Zealand Pharma A/S Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Zealand Pharma A/S' next earnings date is estimated for Wednesday, May 7, 2025, based on past reporting schedules.

Conference Call Resources

Zealand Pharma A/S Earnings Headlines

U.S. Stock Market Now on Verge of Collapse
The last time the U.S. economy looked like this, stocks didn't move for 16 years... And many investors lost 80% of their wealth in real terms. But before you touch any of your holdings – or buy anything – please review my latest warning about the U.S. stock market. It's free to watch.
Zealand Pharma appoints Utpal Singh as CSO
See More Zealand Pharma A/S Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Zealand Pharma A/S? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Zealand Pharma A/S and other key companies, straight to your email.

About Zealand Pharma A/S

Zealand Pharma A/S (OTCMKTS:ZLDPF), a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon that is in Phase III clinical trials for treating congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark.

View Zealand Pharma A/S Profile

More Earnings Resources from MarketBeat